Invivyd, a monoclonal antibody devoted to delivering protection from serious viral infectious diseases, announced that it has signed a $30 million term loan facility with Silicon Valley Bank (SVB), a division of First Citizens Bank. The deal allows for drawdown of capital in the future if certain conditions and milestones are met.
Financial Technology Insights: Snap.Build CEO to Lead Emerie.ai in Fintech-AI Fusion
“We are pleased to have secured this term loan facility ahead of important anticipated catalysts, including gaining alignment with the FDA on the regulatory pathway of our pipeline candidate, VYD2311,” said Bill Duke, Chief Financial Officer of Invivyd. “The non-dilutive nature of this financing facility supports balance sheet optionality so the company can focus on per-share value creation.”
Financial Technology Insights: Margarita Finance Launches AI DeFi Assistant ‘Bartender’
About VYD2311
VYD2311 is a novel monoclonal antibody (mAb) candidate being developed for COVID-19 to continue to address the urgent need for new prophylactic and therapeutic options. The pharmacokinetic profile and antiviral potency of VYD2311 may offer the ability to deliver clinically meaningful titer levels through more patient-friendly means such as an intramuscular route of administration.
Financial Technology Insights: SoFi Expands Loan Platform with $3.2 Billion from Fortress, Edge
VYD2311 was engineered using Invivyd’s proprietary integrated technology platform and is the product of serial molecular evolution designed to generate an antibody optimized for neutralizing contemporary virus lineages. VYD2311 leverages the same antibody backbone as pemivibart, Invivyd’s investigational mAb granted emergency use authorization in the U.S. for the pre-exposure prophylaxis (PrEP) of symptomatic COVID-19 in certain immunocompromised patients, and adintrevimab, Invivyd’s investigational mAb that has a robust safety data package and demonstrated clinically meaningful results in global Phase 2/3 clinical trials for the prevention and treatment of COVID-19.
To share your insights with the FinTech Newsroom, please write to us at sudipto@intentamplify.com
Source – PR Newswire
